{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:26:29Z","timestamp":1780097189847,"version":"3.54.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Chinese National Key Technology R&D Program of Ministry of Science and Technology","award":["2017YFC0907604"],"award-info":[{"award-number":["2017YFC0907604"]}]},{"DOI":"10.13039\/501100018537","name":"National\u2002Science\u2002and\u2002Technology\u2002Major\u2002Project\u2002of\u2002the\u2002Ministry\u2002of\u2002Science\u2002and\u2002Technology\u2002of\u2002China","doi-asserted-by":"crossref","award":["2019ZX09734001-002\u2013004"],"award-info":[{"award-number":["2019ZX09734001-002\u2013004"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical and health science and technology innovation project of Chinese Academy of Medical Sciences","award":["2019-I2M-2\u2013008"],"award-info":[{"award-number":["2019-I2M-2\u2013008"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601430"],"award-info":[{"award-number":["81601430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471615"],"award-info":[{"award-number":["81471615"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Connective tissue disease-related thrombocytopenia (CTD-TP) is a problematic disorder in clinical practice. Because the first-line therapy of glucocorticoid and\/or immunosuppressants is not effective for refractory cases, alternative treatment approaches are urgently needed. The present study investigated the efficacy and safety of sirolimus in refractory CTD-TP patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-centre, single-arm, phase II study enrolled 20 refractory CTD-TP patients between September 2017 and September 2018 (registered on ClinicalTrials.gov: NCT03688191). Oral sirolimus administration was dose-adjusted to maintain a therapeutic range of 6\u201315\u2009ng\/ml for 6\u2009months. The primary endpoints were partial and complete remission rates at 6\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve (60%) patients achieved the primary end point with a 50% complete remission rate after 6\u2009months. Among the 14 SLE patients, the overall response rate was 71.4%, with a complete remission rate of 64.3%. None of the primary Sj\u00f6gren's syndrome cases responded to sirolimus. There was no significant difference in baseline clinical characteristics or lymphocyte subpopulations between responders and non-responders. No severe side effect was detected during the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Sirolimus is an effective and safe treatment option for refractory CTD-TP patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>https:\/\/clinicaltrials.gov, NCT03688191.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa645","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T13:03:46Z","timestamp":1600347826000},"page":"2629-2634","source":"Crossref","is-referenced-by-count":24,"title":["Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-9359","authenticated-orcid":false,"given":"Chanyuan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-3043","authenticated-orcid":false,"given":"Dong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2889","authenticated-orcid":false,"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3883-2318","authenticated-orcid":false,"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"2021061821311831700_keaa645-B1","first-page":"213","article-title":"Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both?","volume":"32","author":"Doria","year":"2005","journal-title":"J Rheumatol"},{"key":"2021061821311831700_keaa645-B2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrrheum.2015.172","article-title":"Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases","volume":"12","author":"Perl","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2021061821311831700_keaa645-B3","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021061821311831700_keaa645-B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"2021061821311831700_keaa645-B5","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"2021061821311831700_keaa645-B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11926-016-0622-8","article-title":"Activation of the mechanistic target of rapamycin in SLE: explosion of evidence in the last five years","volume":"18","author":"Oaks","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"2021061821311831700_keaa645-B7","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021061821311831700_keaa645-B8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2021061821311831700_keaa645-B9","first-page":"615","article-title":"Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria","volume":"17","author":"Mosca","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"2021061821311831700_keaa645-B10","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"2021061821311831700_keaa645-B11","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1053\/j.seminhematol.2013.03.015","article-title":"Autoimmunity and novel therapies in immune-mediated thrombocytopenia","volume":"50","author":"Yehudai","year":"2013","journal-title":"Semin Hematol"},{"key":"2021061821311831700_keaa645-B12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/0961203313485489","article-title":"Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature","volume":"22","author":"Jovancevic","year":"2013","journal-title":"Lupus"},{"key":"2021061821311831700_keaa645-B13","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/ker176","article-title":"Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus\u2013a prospective pilot study","volume":"50","author":"Chen","year":"2011","journal-title":"Rheumatology"},{"key":"2021061821311831700_keaa645-B14","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/art.39791","article-title":"Mitochondrial dysfunction in the liver and antiphospholipid antibody production precede disease onset and respond to rapamycin in lupus-prone mice","volume":"68","author":"Oaks","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021061821311831700_keaa645-B15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fphar.2019.00082","article-title":"Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus","volume":"10","author":"Eriksson","year":"2019","journal-title":"Front Pharmacol"},{"key":"2021061821311831700_keaa645-B16","doi-asserted-by":"crossref","first-page":"e12631","DOI":"10.1111\/dth.12631","article-title":"Rapamycin for refractory discoid lupus erythematosus","volume":"31","author":"Herold","year":"2018","journal-title":"Dermatol Ther"},{"key":"2021061821311831700_keaa645-B17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","article-title":"Efficacy and safety of rituximab in systemic lupus erythematosus and Sjogren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases","volume":"21","author":"Jiang","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"2021061821311831700_keaa645-B18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"2021061821311831700_keaa645-B19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"2021061821311831700_keaa645-B20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri3901","article-title":"Regulation of innate immune cell function by mTOR","volume":"15","author":"Weichhart","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2021061821311831700_keaa645-B21","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/annrheumdis-2019-215039","article-title":"Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated","volume":"78","author":"Wu","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2021061821311831700_keaa645-B22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-018-1662-4","article-title":"Role of the mTOR pathway in minor salivary gland changes in Sjogren's syndrome and systemic sclerosis","volume":"20","author":"Soypa\u00e7ac\u0131","year":"2018","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2629\/38695195\/keaa645.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/6\/2629\/38695195\/keaa645.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T21:34:30Z","timestamp":1624052070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/6\/2629\/5983859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,17]]},"published-print":{"date-parts":[[2021,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa645","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2020,11,17]]}}}